{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:01:16Z","timestamp":1793239276469,"version":"4.5.0"},"reference-count":101,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,9,24]],"date-time":"2013-09-24T00:00:00Z","timestamp":1379980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:p>\n                    Obesity has become a growing pandemic of alarming proportions in the developed and developing countries over the last few decades. The most perturbing fact regarding obesity is the increased predisposition for coronary artery disease, congestive heart failure and sudden cardiac death. The modest efficacy of current anti-obesity agents such as orlistat and the increasing withdrawals of several anti-obesity agents such as sibutramine, rimonabant have led to huge gaps in the pharmacotherapy of obesity. Lorcaserin and Phentermine-topiramate combination (phen-top) are two drugs approved by US FDA in 2012. Lorcaserin, a 5HT\n                    <jats:sub>2C<\/jats:sub>\n                    agonist has moderate efficacy with an acceptable safety profile. Clinical trials with Phen-top have shown a reasonable efficacy but at the cost of risks such as teratogenicity and psychiatric disturbances. Cetilistat, a lipase inhibitor is claimed to have superior safety profile to orlistat and is in phase 3 clinical trials. Other promising anti-obesity molecules acting on the gut which are in clinical trials include exenatide and liraglutide. Drugs which act on the monoaminergic and opioid systems include bupropion-naltrexone and bupropion-zonisamide. Other novel first-in-class drugs which have been explored and have limited success in early clinical development include velneperit, tesofensine, and beloranib. Tesofensine is a triple monoamine re-uptake inhibitor, velneperit acts as a neuropeptide Y5 receptor antagonist and beloranib is a methionine amino peptidase 2 inhibitor. Novel targets such as histamine H3 receptor, VEGF, matrix-metalloproteinase, sirtuin receptors are also being investigated. This review is an attempt to describe the new and emerging molecules that are in clinical development for obesity.\n                  <\/jats:p>","DOI":"10.1177\/1074248413501017","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T01:13:56Z","timestamp":1380071636000},"page":"65-76","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":54,"title":["New and Emerging Drug Molecules Against Obesity"],"prefix":"10.1177","volume":"19","author":[{"given":"Melvin","family":"George","sequence":"first","affiliation":[{"name":"Department of Cardiology, SRM Medical College Hospital & Research Centre, Kancheepuram, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthukumar","family":"Rajaram","sequence":"additional","affiliation":[{"name":"Department of Cardiology, SRM Medical College Hospital & Research Centre, Kancheepuram, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elangovan","family":"Shanmugam","sequence":"additional","affiliation":[{"name":"Department of Cardiology, SRM Medical College Hospital & Research Centre, Kancheepuram, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,9,24]]},"reference":[{"key":"bibr1-1074248413501017","unstructured":"WHO. Obesity and Overweight [Internet]; 2013. http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/. Accessed May 23, 2013."},{"key":"bibr2-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1998.tb00322.x"},{"key":"bibr3-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.189702"},{"key":"bibr4-1074248413501017","unstructured":"Obesity to Overtake Smoking as Leading Cause of Death [Internet]; 2013. \nhttp:\/\/www.medscape.com\/viewarticle\/474966. Accessed May 31, 2013."},{"key":"bibr5-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.068"},{"key":"bibr6-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2009.00598.x"},{"key":"bibr7-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1903"},{"key":"bibr8-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1960"},{"key":"bibr9-1074248413501017","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831010-00005"},{"key":"bibr10-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1185\/03007997309111712"},{"key":"bibr11-1074248413501017","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629040-00001"},{"key":"bibr12-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1124\/pr.59.2.2"},{"key":"bibr13-1074248413501017","unstructured":"BELVIQ\u2014022529lbl.pdf [Internet]; 2013. \nhttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022529lbl.pdf. Accessed May 23, 2013."},{"key":"bibr14-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133348"},{"key":"bibr15-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809103391103"},{"key":"bibr16-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.043448"},{"key":"bibr17-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.043414"},{"key":"bibr18-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909809"},{"key":"bibr19-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1256"},{"key":"bibr20-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.66"},{"key":"bibr21-1074248413501017","unstructured":"Persistent Concerns About Lorcaserin (Lorqess) From FDA Reviewers [Internet]. Forbes; 2013. http:\/\/www.forbes.com\/sites\/larryhusten\/2012\/05\/08\/persistent-concerns-about-lorcaserin-lorqe-ss-from-fda-reviewers\/. Accessed May 24, 2013."},{"key":"bibr22-1074248413501017","unstructured":"Press Announcements > FDA approves Belviq to treat some overweight or obese adults [Internet]; 2013. \nhttp:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm309993.htm. Accessed May 26, 2013."},{"key":"bibr23-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"bibr24-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"bibr25-1074248413501017","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927"},{"key":"bibr26-1074248413501017","first-page":"267","volume":"7","author":"Uwaifo G","year":"2011","journal-title":"Drug Des Devel Ther"},{"key":"bibr27-1074248413501017","unstructured":"Risk Evaluation and Mitigation Strategy (REMS). Qsymia\n                      \u00ae\n                      (phentermine and topiramate extended-release) capsules CIV [Internet]; 2013. http:\/\/www.qsymiarems.com\/. Accessed May 31, 2013."},{"key":"bibr28-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"bibr29-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"bibr30-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309"},{"key":"bibr31-1074248413501017","unstructured":"Orexigen Therapeutics, Inc.\u2014Contrave [Internet]; 2013. http:\/\/www.orexigen.com\/product-candidates\/contrave.html. Accessed June 3, 2013."},{"key":"bibr32-1074248413501017","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0809"},{"key":"bibr33-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.82"},{"key":"bibr34-1074248413501017","unstructured":"Orexigen Therapeutics, Inc.\u2014Press Release [Internet]; 2013. \nhttp:\/\/ir.orexigen.com\/phoenix.zhtml?c=207034&p=irol-newsArticle&id=1400316. Accessed May 23, 2013."},{"issue":"41","key":"bibr35-1074248413501017","first-page":"2974","volume":"171","author":"Nielsen A-LH","year":"2009","journal-title":"Laeger"},{"issue":"7","key":"bibr36-1074248413501017","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1517\/13543780902967632","volume":"18","author":"Doggrell SA.","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"bibr37-1074248413501017","unstructured":"Trial irregularities earn Lancet study of potential weight loss drug tesofensine Expression of Concern. Retraction Watch [Internet]; 2013. \nhttp:\/\/retractionwatch.wordpress.com\/2013\/04\/09\/trial-irregularities-earn-lancet-study-of-potential-weight-loss-drug-tesofensine-expression-of-concern\/. Accessed May 23, 2013."},{"key":"bibr38-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/0195-6663(91)90062-W"},{"key":"bibr39-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-7634(02)00041-6"},{"key":"bibr40-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2010.00172.x"},{"key":"bibr41-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011421785"},{"key":"bibr42-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0803446"},{"key":"bibr43-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.155"},{"key":"bibr44-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.57"},{"key":"bibr45-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61375-1"},{"key":"bibr46-1074248413501017","unstructured":"Search of: liraglutide AND obesity\u2014List Results\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/www.clinicaltrials.gov\/ct2\/results?term=liraglutide+AND+obesity&Search=Search. Accessed May 23, 2013."},{"key":"bibr47-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d7771"},{"key":"bibr48-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00384.2012"},{"key":"bibr49-1074248413501017","unstructured":"Search of: PF-04620110\u2014List Results\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/www.clinicaltrials.gov\/ct2\/results?term=PF-04620110&Search=Search. Accessed May 28, 2013."},{"key":"bibr50-1074248413501017","unstructured":"The Science\u2014Our Approach\u2014Zafgen [Internet]; 2013. http:\/\/zafgen.com\/zafgen\/our-approach\/the-science. Accessed May 24, 2013."},{"key":"bibr51-1074248413501017","volume-title":"Obes (Silver Spring)","author":"Hughes TE","year":"2013"},{"key":"bibr52-1074248413501017","unstructured":"Search of: beloranib\u2014List Results\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/www.clinicaltrials.gov\/ct2\/results?term=beloranib&Search=Search. Accessed May 24, 2013."},{"key":"bibr53-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.10.002"},{"key":"bibr54-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-245-8_5"},{"key":"bibr55-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2009.08.006"},{"key":"bibr56-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvm007"},{"key":"bibr57-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802987"},{"key":"bibr58-1074248413501017","unstructured":"npre20116256-1.pdf [Internet]; 2013. \nhttp:\/\/precedings.nature.com\/documents\/6256\/version\/1\/files\/npre20116256-1.pdf. Accessed May 28, 2013."},{"key":"bibr59-1074248413501017","unstructured":"nyhf2_10_hottechnologies_angiolab.pdf [Internet]; 2013. \nhttp:\/\/www.nyhf.org\/docs\/nyhf2_10_hottechnologies_angiolab.pdf. Accessed May 28, 2013."},{"key":"bibr60-1074248413501017","doi-asserted-by":"publisher","DOI":"10.3109\/13880209.2010.539617"},{"key":"bibr61-1074248413501017","unstructured":"Takeda Submits a New Drug Application for Cetilistat (Development Code: ATL-962) in Japan for the Treatment of Obesity with Complications. Takeda Pharmaceutical Company Limited [Internet]; 2013. http:\/\/www.takeda.com\/news\/2012\/20121030_4004.html. Accessed June 1, 2013."},{"key":"bibr62-1074248413501017","unstructured":"Cardiovascular Outcomes Study of Naltrexone SR\/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)\u2014Full Text View\u2014ClinicalTrials.gov [Internet]; 2013. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01601704?term=contrave&rank=3. Accessed June 1, 2013."},{"key":"bibr63-1074248413501017","unstructured":"Orexigen Therapeutics, Inc.\u2014Empatic [Internet]; 2013. http:\/\/www.orexigen.com\/product-candidates\/empatic.html. Accessed June 1, 2013."},{"key":"bibr64-1074248413501017","unstructured":"Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE\n                      TM\n                      \u2014Obesity and Pre-diabetes\u2014Full Text View\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT01272219?term=Liraglutide+AND+obesity&rank=1. Accessed June 1, 2013."},{"key":"bibr65-1074248413501017","unstructured":"Search of: velneperit\u2014List Results\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/clinicaltrials.gov\/ct2\/results?term=velneperit&Search=Search. Accessed June 1, 2013."},{"key":"bibr66-1074248413501017","unstructured":"Search of: tesofensine\u2014List Results\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/www.clinicaltrials.gov\/ct2\/results\/displayOpt?flds=a&flds=b&flds=f&submit_fld_opt=on&term=tesofensine&show _flds=Y. Accessed June 1, 2013."},{"key":"bibr67-1074248413501017","unstructured":"A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients\u2014Full Text View\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/clinicaltrials.gov\/ct2\/show\/NCT00622765. Accessed June 1, 2013."},{"key":"bibr68-1074248413501017","unstructured":"Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss\u2014Full Text View\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00779519?term=TTP435&rank=1. Accessed June 3, 2013."},{"key":"bibr69-1074248413501017","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.8.2390"},{"key":"bibr70-1074248413501017","unstructured":"Search of: GSK 1521498\u2014List Results\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/www.clinicaltrials.gov\/ct2\/results\/displayOpt?flds=a&flds=b&flds=f&submit_fld_opt=on&term=GSK+1521498&show_flds=Y. Accessed May 27, 2013."},{"key":"bibr71-1074248413501017","unstructured":"Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement\u2014Full Text View\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01039454?term=GSK+598809+AND+obesity&rank=1. Accessed June 1, 2013."},{"key":"bibr72-1074248413501017","unstructured":"Search of: PF-04971729 AND obesity\u2014List Results\u2014ClinicalTrials.gov [Internet]; 2013.\n \nhttp:\/\/www.clinicaltrials.gov\/ct2\/results?term=PF-04971729+AND+obesity&Search=Search. Accessed June 1, 2013."},{"key":"bibr73-1074248413501017","unstructured":"Search of: PF-04620110 AND obesity\u2014List Results\u2014ClinicalTrials.gov [Internet]; 2013.  http:\/\/www.clinicaltrials.gov\/ct2\/results?term=PF-04620110+AND+obesity&Search=Search. Accessed June 1, 2013."},{"key":"bibr74-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2136"},{"key":"bibr75-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.6.1083"},{"key":"bibr76-1074248413501017","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565100-00006"},{"key":"bibr77-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350901"},{"key":"bibr78-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809103391102"},{"key":"bibr79-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.126733"},{"key":"bibr80-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.15.1814"},{"key":"bibr81-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432501"},{"key":"bibr82-1074248413501017","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-7-200504050-00012"},{"key":"bibr83-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.05.011"},{"key":"bibr84-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.4.494"},{"key":"bibr85-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.01.006"},{"key":"bibr86-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.113905"},{"key":"bibr87-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.09.007"},{"key":"bibr88-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-009-0056-y"},{"key":"bibr89-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61721-8"},{"key":"bibr90-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61705-X"},{"key":"bibr91-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"bibr92-1074248413501017","unstructured":"Amylin and Takeda Discontinue Development of Pramlintide\/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program. Takeda Pharmaceutical Company Limited [Internet]; 2013.  http:\/\/www.takeda.com\/news\/2011\/20110805_3889.html. Accessed June 3, 2013."},{"key":"bibr93-1074248413501017","unstructured":"Proefschrift Edwin Parlevliet 180810-06.pdf [Internet]; 2013. \nhttps:\/\/openaccess.leidenuniv.nl\/bitstream\/handle\/1887\/16080\/06.pdf?sequence=9. Accessed May 24, 2013."},{"key":"bibr94-1074248413501017","unstructured":"A Weight Loss Study in Overweight Men and Women\u2014Full Text View\u2014ClinicalTrials.gov [Internet]; 2013. \nhttp:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00993421?term=LY377604&rank=1. Accessed June 3, 2013."},{"key":"bibr95-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2008.135"},{"key":"bibr96-1074248413501017","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.110.001586"},{"key":"bibr97-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2010.21"},{"key":"bibr98-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.167"},{"key":"bibr99-1074248413501017","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03549.x"},{"key":"bibr100-1074248413501017","unstructured":"Guideline on Weight Control\u2014Adopted\u2014WC500003264.pdf [Internet]; 2013. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003264.pdf. Accessed June 3, 2013."},{"key":"bibr101-1074248413501017","unstructured":"Guidance for Industry Developing Products for Weight Management\u2014ucm071612.pdf [Internet]; 2013. http:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm071612.pdf. Accessed June 3, 2013."}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248413501017","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1074248413501017","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248413501017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:41:52Z","timestamp":1777394512000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248413501017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,24]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1177\/1074248413501017"],"URL":"https:\/\/doi.org\/10.1177\/1074248413501017","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,24]]}}}